Regulator cited significant uncertainties about the drug’s benefits, as well as the high costs to treat its severe side ...

Eli Lilly's treatment for early Alzheimer's was deemed too expensive for wide use by UK's cost-effectiveness body on ...

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and ...

Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after ...

Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too ...

A counter lawsuit asking a judge to force two Waynesboro Board of Election members to certify the Nov. 5 election was filed ...

"Slim Aarons: Gold Coast" is organized by Shawn Waldron, the curator for Getty Images and manager of the Slim Aarons Archive ...

Currently, financial markets are experiencing a mix of optimism and caution as investors react to changing economic ...

The U.K. watchdog declines to endorse Eli Lilly's Alzheimer's drug donanemab, citing lack of value for the NHS and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the ...

A group of U.S. senators are digging into the direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer this ...